Thelansis

Chronic Hepatitis B Emerging Therapy and TPP Insights Thelansis’s “Chronic Hepatitis B Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Key business questions answered: Detailed emerging competitive landscape Pipeline analysis Target patients for emerging therapies Key companies Key mechanism of actions Launch date estimates, etc. Clinical trial landscape analysis Target patient segments Trial endpoints Trial design Recruitment criteria, etc. Unmet Needs and Opportunities Performance of key current therapies Top areas of unmet needs Opportunity sizing for key unmet needs Target Product Profiles Attri...

Chronic Hepatitis B Emerging Therapy Thelansis’s “Chronic Hepatitis B Emerging Therapy, with Unmet Needs and TPP Insights Report – 2024 To 2034″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Chronic Hepatitis B Overview Chronic Hepatitis B (CHB) infection is characterized by the presence of Hepatitis B surface antigen (HBsAg) in the serum for at least six months. Whereas HBsAg indicates the presence of hepatitis B viral infection, the markers HBeAg and HBV DNA, as determined by polymerase chain reaction (PCR) assays, are indicators of viral replication and infectivity. Severe complications associated with chronic infection encompass cirrhosis, liver failure, hepatocellular carcinoma, and mortality. In a minority of cases, HBV DNA can be detected in the serum without concurrent HBe...